

Bio-Gene to expand Flavocide® and Qcide® vector control evaluation to Asia

Highlights

- Bio-Gene to evaluate the use of Flavocide® and Qcide® in Asia for potential use in vector control programs against a range of mosquitoes that spread disease
- Includes evaluation against mosquito species that carry Dengue fever, Chikungunya fever and Zika virus infection
- Major opportunity for Bio-Gene across Asia to provide innovative mosquito control options for control of endemic mosquito species, including those that have developed resistance to currently available insecticidal products

Bio-Gene Technology Limited (ASX: BGT, Bio-Gene or the Company), an Australian company developing the next generation of novel insecticides derived from nature, is pleased to announce that it is expanding evaluation of both Flavocide® and Qcide® into Asia for their efficacy against a range of mosquitoes that carry diseases.

This work will evaluate the susceptibility of the most prevalent mosquito species present in Singapore, and in other countries in the region, to both Flavocide and Qcide in accordance with guidelines published by the World Health Organisation (**WHO**). The initial phase of the evaluation is anticipated to be completed by Q3 2026. The results of that evaluation will guide the commercialisation of Flavocide and Qcide and their use in vector control programs in the region.

Various species of mosquitoes present in countries such as Singapore, including *Aedes aegypti*, *Aedes albopictus* and *Culex quinquefasciatus*, are vectors of diseases including Dengue fever, Chikungunya fever and Zika virus infection. Dengue fever is a debilitating disease spread by mosquitoes, with Singapore experiencing seasonal outbreaks and reporting annual cases of between 3,990 and 13,651 during the last seven years.¹

In addition, other mosquito borne diseases such as West Nile virus, Japanese encephalitis and St. Louis encephalitis have been detected in the region, although they are not usually endemic. As part of the program, Flavocide and Qcide will be evaluated against three of the primary mosquito species involved in the potential spread of these diseases.

Due to the increasing level of mosquito resistance to currently used insecticides, the development of new insecticides with novel modes of action is essential to provide new insect control options using Integrated Pest Management (**IPM**) systems. Both Flavocide and Qcide

¹ See: [Chapter 3 - Vector Borne Diseases, Communicable Diseases Surveillance in Singapore 2023-2024, Communicable Disease Agency, Singapore](#)

exert their insecticidal effect on mosquitoes via an innovative and unique mode of action and therefore have the potential to provide new options for the control of endemic mosquito species, including those that have developed resistance to currently available insecticidal products.

The use of safe and sustainable treatment options is a key objective of a number of the mosquito control programs across the Asian region. Bio-Gene's insecticidal active Qcide is a natural oil extracted using steam distillation from the harvested leaf biomass produced by a sub-type of *Eucalyptus cloeziana*, also known as Gympie messmate. Flavocide is based on flavesone that is a natural plant compound produced by the same *Eucalyptus* species.

Tim Grogan, Bio-Gene Technology's Managing Director & CEO said:

"We are very pleased to be expanding the evaluation of both Flavocide and Qcide into Asia. The potential for mosquitoes in the Asian region to develop increasing levels of resistance to the currently available insecticides means that the successful evaluation of Flavocide and Qcide can assist in the development of more effective pest management options for potential use in the region."

"The data generated from this work will assist Bio-Gene in its assessment of the utility of Flavocide and Qcide for use against mosquitoes in the region. This evaluation work will also be instructive in assessing the efficacy of the innovative mode of action of both Flavocide and Qcide against the endemic mosquito species, and their pedigree as potential new mosquito control agents derived from nature."

Approved for release on ASX by Bio-Gene Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited.

To subscribe to Bio-Gene's announcements and other forms of email communication, please visit [this page](#) of our website.

www.bio-gene.com.au
